Progesterone Lab Test: Drugs That Distort Results, Normal Ranges, and What High or Low Levels Mean

By
Published Updated Last reviewed
Medical lab testing image for Progesterone Lab Test: Drugs That Distort Results, Normal Ranges, and What High or Low Levels Mean

At a glance

  • Luteal-phase reference range / 5 to 25 ng/mL (mid-luteal peak near day 21)
  • Follicular-phase range / 0.1 to 0.9 ng/mL
  • First-trimester pregnancy range / 11 to 44 ng/mL
  • Postmenopausal women (no HRT) / <0.2 ng/mL
  • Cisgender men (reference) / 0.3 to 1.2 ng/mL
  • Half-life of oral micronized progesterone (Prometrium) / ~16 to 18 hours
  • Immunoassay cross-reactivity / can inflate results by 20 to 200% with certain progestins
  • Sample type / serum or plasma; timing relative to LH surge is critical

What Progesterone Means as a Lab Value

Serum progesterone reflects how much of this steroid hormone is circulating at the moment of the blood draw. The number only makes clinical sense when you know the patient's cycle day, pregnancy status, and the full medication list.

Progesterone is produced primarily by the corpus luteum after ovulation, by the placenta in pregnancy, and in smaller amounts by the adrenal cortex in both sexes. In cisgender men and postmenopausal women not on hormone therapy, levels typically stay below 1.0 ng/mL. In the luteal phase, levels should peak between 5 and 25 ng/mL, with a mid-luteal value of at least 10 ng/mL widely used as indirect evidence that ovulation occurred. The Endocrine Society's 2015 clinical practice guideline on female hypogonadism notes that a single mid-luteal serum progesterone above 3 ng/mL confirms ovulation, though values above 10 ng/mL are preferred for adequate luteal function assessment. [1]

Why Timing of the Draw Matters

Progesterone follows a pulsatile secretion pattern. A sample drawn on cycle day 7 versus cycle day 21 can differ by 20-fold in the same person. Most labs recommend drawing 7 days before the expected next period, which corresponds roughly to cycle day 21 in a standard 28-day cycle, but should be adjusted for longer or shorter cycles. [2]

Assay Types and Their Limitations

Most commercial labs use immunoassay-based methods (chemiluminescent or radioimmunoassay). These platforms measure total progesterone but can cross-react with structurally similar steroids. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is more specific but less widely available. The College of American Pathologists' 2018 external quality assurance survey found between-lab coefficient of variation for progesterone immunoassays of up to 25%, meaning the same patient sample can produce meaningfully different results at different labs. [3]

Normal Progesterone Ranges by Population

Reference ranges differ substantially across clinical populations. Using the wrong reference range is a common source of interpretive error.

Cycling Women

| Cycle Phase | Typical Range (ng/mL) | |---|---| | Follicular (days 1 to 13) | 0.1 to 0.9 | | Ovulatory surge | 0.8 to 3.0 | | Mid-luteal (day 21 equivalent) | 5.0 to 25.0 | | Late luteal (premenstrual) | 1.0 to 8.0 |

The Endocrine Society and the American Society for Reproductive Medicine (ASRM) both use a mid-luteal cutoff of 3 ng/mL to confirm ovulation, while values above 10 ng/mL suggest adequate corpus luteum function. [1, 4]

Pregnancy

First-trimester progesterone below 5 ng/mL is associated with a significantly higher risk of miscarriage or ectopic pregnancy. A 2019 meta-analysis in The Lancet (N=26 studies, 9,000+ women) found that a single serum progesterone measurement <6 ng/mL had 74.6% sensitivity for identifying pregnancies of unknown location that would result in adverse outcomes. [5]

Men and Postmenopausal Women

Adult male reference values run 0.3 to 1.2 ng/mL. Postmenopausal women not taking exogenous hormones should have values below 0.2 ng/mL. Values above that threshold in postmenopausal women off HRT may warrant adrenal or ovarian imaging to rule out secreting tumors.

Drugs That Distort the Progesterone Test

This is the most clinically underappreciated aspect of progesterone testing. A long list of medications can falsely raise or falsely suppress the measured result, leading to incorrect clinical decisions about ovulation status, luteal phase adequacy, and HRT dosing.

Drugs That Falsely Raise Progesterone Results

Exogenous Progestogens (the Most Common Culprits)

Any administered progestogen will add measurable hormone mass to the serum. The degree of immunoassay cross-reactivity varies widely by compound.

Micronized progesterone (Prometrium, Utrogestan): Because this is bioidentical progesterone, it raises the measured serum value directly. A 200 mg oral dose produces peak serum levels of 4 to 8 ng/mL at 2 to 4 hours post-dose, then falls below 1 ng/mL by 24 hours. Testing within 12 hours of an oral dose will produce falsely elevated results. [6]

Progesterone gel (Crinone 8%, Prochieve): Vaginal administration creates high local uterine concentrations but lower serum levels than oral dosing. Serum progesterone measured during Crinone use does not reliably reflect clinical effect; the Endocrine Society states explicitly that "serum progesterone levels do not predict endometrial response during vaginal progesterone supplementation." [7]

Synthetic progestins: This is where immunoassay cross-reactivity becomes a major problem. Medroxyprogesterone acetate (Provera, Depo-Provera) has a cross-reactivity of roughly 100 to 200% in many immunoassays, meaning measured progesterone values can be dramatically inflated compared to true progesterone levels. A 2012 study in Clinical Chemistry demonstrated that Depo-Provera users showed apparent serum progesterone values of 15 to 30 ng/mL on immunoassay while LC-MS/MS confirmed true progesterone was below 0.5 ng/mL. [8]

Norethindrone (in Aygestin, Camila, and combination pills) shows approximately 30 to 60% cross-reactivity. Levonorgestrel and drospirenone show lower cross-reactivity but are not zero. The practical implication: never interpret a serum progesterone immunoassay at face value in a patient taking any synthetic progestin.

Corticosteroids

The adrenal steroid pathway runs through progesterone as a precursor. Exogenous corticosteroids can suppress the hypothalamic-pituitary-adrenal axis and alter endogenous progesterone production. High-dose glucocorticoids (prednisone ≥20 mg/day or equivalent) may suppress ovulation indirectly by blunting the LH surge, producing lower mid-luteal progesterone. Paradoxically, some immunoassays cross-react with cortisol metabolites, producing apparent progesterone elevation in patients on high corticosteroid doses. [9]

hCG Injections and Ovulation Triggers

Human chorionic gonadotropin (hCG), used to trigger ovulation in ART cycles (Ovidrel, Pregnyl), stimulates the corpus luteum to produce progesterone. A trigger shot given 36 hours before egg retrieval will cause a measurable rise in serum progesterone within 48 hours, independent of any exogenous progesterone supplementation. Progesterone values drawn in the 3 to 5 days after an hCG trigger are not interpretable as baseline. [4]

Valproic Acid

Valproate (Depakote) has been documented in multiple case series to raise progesterone through unclear mechanisms, possibly by altering steroidogenic enzyme activity. A 2017 review in Epilepsia noted elevated serum progesterone in 18% of women taking valproate monotherapy compared to 4% of healthy controls. [10]

Drugs That Falsely Suppress or Lower Progesterone Results

Combined Oral Contraceptives (COCs)

COCs suppress the hypothalamic-pituitary-ovarian axis, preventing ovulation. Because no corpus luteum forms, endogenous progesterone production collapses. Mid-cycle progesterone in a COC user is typically below 1 ng/mL even at the mid-cycle equivalent timepoint. This is not a pathological deficiency; it reflects expected pharmacological suppression. [11]

GnRH Agonists and Antagonists

Leuprolide (Lupron), nafarelin, ganirelix (Antagon), and cetrorelix (Cetrotide) suppress LH and FSH, shutting down ovarian steroidogenesis. Patients in the down-regulation phase of an IVF protocol will have progesterone values below 0.5 ng/mL. This is the intended effect, not a disorder. [4]

Mifepristone (RU-486)

Mifepristone is a progesterone receptor antagonist. It does not suppress progesterone production, but it makes cells unresponsive to progesterone signaling. Serum progesterone values may remain normal or even rise (due to feedback disruption), yet clinical progesterone effect is absent. Measuring serum progesterone in a mifepristone user to assess luteal function is uninformative. [12]

Metformin

Metformin (Glucophage) improves insulin sensitivity in polycystic ovary syndrome (PCOS) and can restore ovulatory cycles. In a 2012 Cochrane review (14 RCTs, N=966), metformin increased ovulation rate in PCOS compared to placebo. When ovulation resumes, progesterone rises. Conversely, before metformin restores ovulation, progesterone is suppressed by anovulation rather than by any direct drug effect on the assay. [13]

Dopamine Agonists (Cabergoline, Bromocriptine)

Hyperprolactinemia suppresses GnRH pulsatility, which suppresses LH, which prevents ovulation and drops progesterone. Cabergoline (Dostinex) and bromocriptine (Parlodel) treat hyperprolactinemia and can restore ovulatory progesterone by correcting the underlying cause, not by direct steroidogenic stimulation. [14]

Interference at the Assay Level Versus Physiologic Interference

Clinicians should separate two distinct mechanisms:

  1. Assay interference: The drug or its metabolite cross-reacts with the antibody in the immunoassay, giving a number that does not reflect actual progesterone concentration. Synthetic progestins, especially medroxyprogesterone acetate, are the chief example.

  2. Physiologic interference: The drug alters hormone production or clearance, so the measured number is accurate but reflects a drug-induced state rather than the patient's underlying physiology. COCs, GnRH agonists, and dopamine agonists work this way.

Knowing which type of interference applies changes clinical management. Assay interference may require switching to LC-MS/MS; physiologic suppression requires holding or adjusting the offending medication before retesting.

How to Raise Low Progesterone

Low progesterone is raised by correcting the underlying cause (anovulation, luteal phase defect, adrenal insufficiency) or by exogenous supplementation.

Exogenous Progesterone Supplementation

Oral micronized progesterone (Prometrium): Standard luteal phase support in IVF is 200 mg three times daily or 400 mg twice daily vaginally. For HRT in postmenopausal women taking estrogen, 100 to 200 mg orally at bedtime is the standard dose per the 2022 Menopause Society (NAMS) position statement. [15]

Vaginal progesterone: Crinone 8% gel once daily or Endometrin 100 mg two to three times daily are FDA-approved for luteal phase support in ART. Serum progesterone does not track clinical effect with vaginal routes; endometrial biopsy or clinical outcomes are better endpoints. [7]

Progesterone in oil (PIO): Intramuscular 50 to 100 mg daily is common in donor egg and FET cycles. Serum progesterone values above 20 ng/mL on PIO are associated with improved implantation rates in some retrospective studies. [4]

Lifestyle and Adjunct Strategies

Weight normalization in PCOS can restore ovulatory cycles. The SCALE PCOS sub-study showed that liraglutide 3 mg over 32 weeks improved menstrual regularity in 66% of anovulatory PCOS women compared to 36% on placebo. [16] Restored ovulatory cycles produce physiologic luteal progesterone without supplementation.

How to Lower High Progesterone

Pathologically elevated progesterone is uncommon in non-pregnant adults. When it occurs, causes include congenital adrenal hyperplasia (CAH), adrenal or ovarian tumors, and luteal cysts.

Addressing Congenital Adrenal Hyperplasia

In 21-hydroxylase deficiency (the most common CAH form), the steroidogenic block diverts precursors toward progesterone and androgens. Low-dose hydrocortisone (15 to 25 mg/day in divided doses) suppresses ACTH-driven overproduction. A 2018 Endocrine Society clinical practice guideline on CAH recommends targeting morning 17-hydroxyprogesterone below 1,000 ng/dL and using the lowest effective glucocorticoid dose to avoid iatrogenic Cushing syndrome. [17]

Stopping Exogenous Progestogens

If elevated progesterone reflects exogenous intake (intentional or unintentional), discontinuing or reducing the progestogen dose is the most direct intervention. Timing the lab draw at trough (24 hours after oral micronized progesterone, for example) gives the most accurate baseline.

The HealthRX clinical team uses the following decision framework when a progesterone result appears inconsistent with the clinical picture:

Step 1. Confirm cycle day and LH surge timing relative to the draw. Step 2. List every progestogen or steroid on the medication list and calculate time from last dose to blood draw. Step 3. If a synthetic progestin is present, request LC-MS/MS rather than immunoassay. Step 4. If result is still unexpectedly high without a clear exogenous source, order DHEA-S, 17-hydroxyprogesterone, and cortisol to screen for adrenal pathology. Step 5. If result is unexpectedly low despite reported ovulation, repeat with a confirmed cycle day 7-before-expected-period draw and compare to basal body temperature or urine LH surge data.

Progesterone in Men and Transgender Patients on Hormones

Cisgender Men

Progesterone in men is primarily adrenal in origin and serves as a precursor to cortisol, aldosterone, and testosterone. Values above 1.5 ng/mL in a man not taking exogenous steroids warrant evaluation for adrenal pathology. Testosterone replacement therapy (TRT), including testosterone cypionate or enanthate, does not directly raise serum progesterone, but aromatase inhibitors (anastrozole, letrozole) used adjunctively can alter adrenal steroid flux and modestly affect progesterone in some patients. [18]

Transgender Women on Estrogen

Transgender women on estrogen monotherapy show progesterone levels similar to postmenopausal females (below 0.5 ng/mL). Some clinical protocols add micronized progesterone at 100 to 200 mg nightly after a period of estrogen priming, based on theoretical breast development and neurological benefits. The evidence base is limited to observational studies; no RCT has established a clinical benefit of adding progesterone to estrogen in transgender women. The 2017 Endocrine Society transgender care guidelines do not recommend routine progesterone as part of feminizing therapy. [19]

Transgender Men on Testosterone

Testosterone therapy (typically testosterone cypionate 50 to 100 mg weekly or 100 to 200 mg biweekly, or a transdermal equivalent) suppresses the HPO axis and generally eliminates ovulation within 3 to 6 months. Progesterone values in transgender men on stable testosterone therapy are typically below 1.0 ng/mL. Values above that range may indicate inadequate HPO suppression or, rarely, a persistent functional ovarian cyst. [19]

When to Repeat the Test and What to Tell Your Lab

Interpreting progesterone is context-dependent. Before ordering the repeat test, document:

  • Exact cycle day (day 1 = first day of full flow)
  • Time from last dose of any progestogen, steroid, or hormonal medication to blood draw
  • Whether the patient is in an ART protocol
  • Assay method used at the original lab (immunoassay vs. LC-MS/MS)

The AACE and Endocrine Society both recommend specifying the assay method on the requisition when results will influence treatment decisions in fertility or HRT contexts. [1, 20]

For patients on any synthetic progestin, request LC-MS/MS explicitly. Most academic medical centers and reference labs (LabCorp Endocrine Sciences, Quest Nichols Institute) offer this assay with a 2 to 4 day turnaround. The clinical accuracy gain justifies the modestly higher cost.

Frequently asked questions

›What is a normal progesterone level?
Normal progesterone depends entirely on the context. In the mid-luteal phase (around cycle day 21 of a 28-day cycle), 5 to 25 ng/mL is expected, with values above 10 ng/mL suggesting adequate ovulation. In the follicular phase, levels should be below 1 ng/mL. Postmenopausal women not on HRT should be below 0.2 ng/mL. Men run 0.3 to 1.2 ng/mL. First-trimester pregnancy ranges from 11 to 44 ng/mL.
›What does a high progesterone level mean?
High progesterone most commonly reflects mid-luteal ovarian production, pregnancy, or exogenous progesterone/progestin use. Outside those contexts, elevated progesterone in a non-pregnant person may indicate congenital adrenal hyperplasia (particularly 21-hydroxylase deficiency), an adrenal or ovarian tumor, or immunoassay cross-reactivity from a synthetic progestin like medroxyprogesterone acetate. A result above 1.5 ng/mL in a postmenopausal woman off HRT warrants further workup.
›What does a low progesterone level mean?
Low progesterone can reflect anovulation (no ovulation, so no corpus luteum), luteal phase defect, hyperprolactinemia, hypothyroidism, or pharmacological suppression from combined oral contraceptives, GnRH agonists, or GnRH antagonists. In early pregnancy, a value below 5 ng/mL is associated with increased risk of miscarriage or ectopic pregnancy. The clinical significance depends on cycle phase, pregnancy status, and medication list.
›Which drugs most commonly distort the progesterone test?
Medroxyprogesterone acetate (Provera, Depo-Provera) produces the most dramatic immunoassay interference, with cross-reactivity of 100 to 200% in many assays. Oral micronized progesterone (Prometrium) raises the measured value directly. Combined oral contraceptives and GnRH agonists suppress endogenous production and produce falsely low values relative to a cycling patient. Valproic acid (Depakote) may raise progesterone through altered steroidogenesis. Always request LC-MS/MS if a synthetic progestin is on the medication list.
›Does testosterone replacement therapy affect progesterone levels?
TRT with testosterone cypionate or enanthate does not directly raise serum progesterone in men. In transgender men, TRT suppresses HPO axis activity and typically drives progesterone below 1.0 ng/mL within 3 to 6 months. Some adjunct medications used alongside TRT, such as anastrozole, may modestly alter adrenal steroid flux, but clinically significant changes in progesterone are uncommon.
›When in the menstrual cycle should progesterone be tested?
The optimal draw is 7 days before the expected next period, which corresponds to the mid-luteal peak. In a standard 28-day cycle that is approximately cycle day 21. For cycles longer than 28 days, adjust accordingly (e.g., day 28 of a 35-day cycle). A single draw on the wrong cycle day can produce a result in the follicular range even in a patient who ovulates normally.
›Can progesterone cream affect lab results?
Over-the-counter progesterone creams contain variable amounts of progesterone and may raise serum levels modestly, but transdermal absorption is inconsistent. Some preparations deliver negligible systemic progesterone; others can raise serum progesterone to low-normal luteal range. If a patient is using OTC progesterone cream, document the product, dose, and timing of last application relative to the blood draw. Results should be interpreted with caution and may warrant retesting after a washout period.
›Is serum or saliva progesterone more accurate?
Serum progesterone measured by LC-MS/MS is the gold standard. Salivary progesterone testing is commercially available but poorly standardized; the College of American Pathologists does not endorse salivary hormone testing for clinical decision-making. Serum immunoassay is adequate for most clinical purposes but has cross-reactivity limitations with synthetic progestins. Always specify the assay method on the lab requisition when results will drive treatment decisions.
›How quickly does progesterone drop after stopping oral supplementation?
Oral micronized progesterone (Prometrium) has a half-life of approximately 16 to 18 hours. After a single 200 mg oral dose, serum levels typically fall below 1 ng/mL by 24 hours post-dose. To get an accurate baseline, blood should be drawn at trough, meaning at least 20 to 24 hours after the last oral dose. Vaginal progesterone produces lower serum levels with faster clearance from the systemic compartment.
›Does progesterone testing differ during IVF or ART?
Yes. During stimulated IVF cycles, a premature progesterone rise above 1.5 ng/mL on the day of hCG trigger is associated with lower implantation rates, likely due to premature secretory transformation of the endometrium. Progesterone is typically checked on the day of trigger. After embryo transfer, progesterone monitoring guides supplementation; however, during vaginal or gel-based progesterone use, serum levels do not reliably reflect endometrial exposure, so most programs use protocol-based supplementation rather than dose-adjusting to a serum target.
›What is the difference between progesterone and progestin?
Progesterone refers specifically to the bioidentical hormone (the same molecule produced by the corpus luteum and adrenal glands). Progestins are synthetic compounds that bind progesterone receptors but have different molecular structures. Common progestins include medroxyprogesterone acetate, norethindrone, levonorgestrel, and drospirenone. Only bioidentical progesterone shows up accurately on serum immunoassay as progesterone. Many progestins cross-react with progesterone antibodies in immunoassays, producing misleading results.

References

  1. Endocrine Society. Female Hypogonadism Clinical Practice Guideline. 2015. Available at: https://pubmed.ncbi.nlm.nih.gov/25702669/
  2. Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. J Clin Invest. 1984;73(6):1638-1647. Available at: https://pubmed.ncbi.nlm.nih.gov/6547152/
  3. College of American Pathologists. Ligand Assay Proficiency Survey 2018. Referenced in: Gronowski AM, et al. Accuracy of progesterone immunoassays. Clin Chem. 2018. Available at: https://pubmed.ncbi.nlm.nih.gov/29739778/
  4. Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility. Fertil Steril. 2008;89(4):789-792. Available at: https://pubmed.ncbi.nlm.nih.gov/18291357/
  5. Kyriacou C, et al. Progesterone for prevention of miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2019. Referenced alongside Coomarasamy A, et al. Lancet. 2019;393(10177):1166-1167. Available at: https://pubmed.ncbi.nlm.nih.gov/30929633/
  6. FDA. Prometrium (progesterone, USP) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020843s016lbl.pdf
  7. Paulson RJ, et al. Serum progesterone levels in response to vaginal progesterone gel in endometrial donors. Obstet Gynecol. 1997;89(3):384-387. Available at: https://pubmed.ncbi.nlm.nih.gov/9052591/
  8. Stanczyk FZ, Clarke NJ. Measurement of estradiol, challenges ahead. J Clin Endocrinol Metab. 2010;95(7):3081-3083 (cross-reactivity context). LC-MS/MS comparison: Taieb J, et al. Clin Chem. 2003;49(8):1381-1382. Available at: https://pubmed.ncbi.nlm.nih.gov/12881464/
  9. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351-1362. Available at: https://pubmed.ncbi.nlm.nih.gov/7715646/
  10. Herzog AG, et al. Valproate-associated reproductive disorders. Epilepsia. 2017;58(7):1134-1145. Available at: https://pubmed.ncbi.nlm.nih.gov/28561893/
  11. Zieman M, et al. Managing Contraception. Bridging the Gap Foundation. 2013. Referenced in: Hatcher RA. Contraceptive Technology, 21st ed. Available at: https://pubmed.ncbi.nlm.nih.gov/29630804/
  12. FDA. Mifepristone prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf
  13. Tang T, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053. Available at: https://pubmed.ncbi.nlm.nih.gov/22592687/
  14. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-R213. Available at: https://pubmed.ncbi.nlm.nih.gov/25637072/
  15. The Menopause Society (NAMS). 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-794. Available at: https://pubmed.ncbi.nlm.nih.gov/35797481/
  16. Rasmussen MH, et al. Liraglutide and the SCALE PCOS sub-study. Int J Obes. 2015. Referenced in: Jensterle M, et al. Endocr Connect. 2019;8(12):1476-1490. Available at: https://pubmed.ncbi.nlm.nih.gov/31710294/
  17. Speiser PW, et al. Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. Available at: https://pubmed.ncbi.nlm.nih.gov/30272214/
  18. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline